UK pharma giant AstraZeneca has reported 4% sales growth and a 3% increase in revenue for the last quarter of 2017 – though annual profits were down 25%.
Fourth-quarter revenue was $5.77bn compared with $5.58bn in 2016.
However, operating profits for Q4 were $686m, a 73% fall on the same period in 2016, when the company generated profits of $2.53bn.
Over the full financial year, operating profit in 2017 was 25% down at $3.67bn compared with $4.90bn in 2016.
Full-year revenue was $22.46bn, compared with $23.0bn in 2016, a drop of 2%.